HC Wainwright & Co. Maintains Buy on Aquestive Therapeutics, Lowers Price Target to $5
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aquestive Therapeutics (NASDAQ:AQST) with a Buy and lowers the price target from $8 to $5.
63 Biggest Movers From Yesterday
Gainers
Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Thursday after the company announced it received notification of euro 782.1 million of funding from the Greek State for the IPCEI Green HiPo project.
The Daily Biotech Pulse: Roche’s Alzheimer’s Drug Fails, Advisors Back Pfizer, Moderna Shots For Youngest Kids, Valneva Settles COVID-19 Pact With UK
Here's a roundup of top developments in the biotech space over the last 24 hours:
Aquestive Therapeutics Reports Initial Topline Data from Part 3 of EPIPHAST Trial Evaluating AQST-109 Epinephrine Oral Film
AQST-109 is the first and only orally delivered epinephrine product candidate in clinical development
Fastest median time to maximum concentration (Tmax) in studies to date at 12 minutes
Study continues to
Aquestive Therapeutics, Inc. Announces $8.5M Registered Direct Offering
Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today
Stocks That Hit 52-Week Lows On Friday
During Friday's trading, 69 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
During the Thursday's session, 100 stocks hit new 52-week lows.
Earnings Scheduled For May 3, 2022
Companies Reporting Before The Bell
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) is projected to report earnings for its first quarter.
Earnings Outlook For Aquestive Therapeutics
Aquestive Therapeutics (NASDAQ:AQST) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement.
Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.41.